These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 37311494

  • 1. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z, Sharma R, Hamad L, Riebandt G, Attwood K.
    Diabetes Res Clin Pract; 2023 Aug; 202():110776. PubMed ID: 37311494
    [Abstract] [Full Text] [Related]

  • 2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Aug; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 3. Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus.
    Shen M, Chen D, Zhao R, Zheng X, Gu Y, Yang T, Shi Y.
    Front Endocrinol (Lausanne); 2023 Aug; 14():1213225. PubMed ID: 37554766
    [Abstract] [Full Text] [Related]

  • 4. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Aug; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 5. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
    Daban A, Gonnin C, Phan L, Saldmann A, Granier C, Lillo-Lelouet A, Le Beller C, Pouchot J, Weiss L, Tartour E, Fabre E, Medioni J, Oudard S, Vano YA, Dragon-Durey MA, Simonaggio A.
    Oncoimmunology; 2023 Aug; 12(1):2204754. PubMed ID: 37187974
    [Abstract] [Full Text] [Related]

  • 6. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
    Byun DJ, Braunstein R, Flynn J, Zheng J, Lefkowitz RA, Kanbour S, Girotra M.
    Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
    [Abstract] [Full Text] [Related]

  • 7. Identification of Immune Checkpoint Inhibitor-Induced Diabetes.
    Ruiz-Esteves KN, Shank KR, Deutsch AJ, Gunturi A, Chamorro-Pareja N, Colling CA, Zubiri L, Perlman K, Ouyang T, Villani AC, Florez JC, Gusev A, Reynolds KL, Miller KK, Udler MS, Sise ME, Rengarajan M.
    JAMA Oncol; 2024 Oct 01; 10(10):1409-1416. PubMed ID: 39207773
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
    Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG.
    Front Endocrinol (Lausanne); 2023 Oct 01; 14():1242830. PubMed ID: 38027216
    [Abstract] [Full Text] [Related]

  • 9. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
    Fischer M, Amos S, Levy L, Pollack R.
    Harefuah; 2021 Oct 01; 160(10):657-662. PubMed ID: 34689435
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.
    Wei HH, Lai YC, Lin G, Lin CW, Chang YC, Chang JW, Liou MJ, Chen IW.
    Diabetol Metab Syndr; 2024 Jan 23; 16(1):26. PubMed ID: 38254155
    [Abstract] [Full Text] [Related]

  • 13. Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab.
    Zand Irani A, Gibbons H, Teh WX.
    BMJ Case Rep; 2023 Apr 03; 16(4):. PubMed ID: 37011994
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
    Kumar R, Chan A, Bandikatla S, Ranjan S, Ngo P.
    Curr Probl Cancer; 2022 Aug 03; 46(4):100864. PubMed ID: 35671576
    [Abstract] [Full Text] [Related]

  • 16. Diabetes mellitus induced by immune checkpoint inhibitors.
    Zheng Z, Liu Y, Yang J, Tan C, Zhou L, Wang X, Xiao L, Zhang S, Chen Y, Liu X.
    Diabetes Metab Res Rev; 2021 Jan 03; 37(1):e3366. PubMed ID: 32543027
    [Abstract] [Full Text] [Related]

  • 17. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 18. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V, Patwari A, Harb AJ.
    J Cancer Res Clin Oncol; 2021 Sep 29; 147(9):2789-2800. PubMed ID: 33774736
    [Abstract] [Full Text] [Related]

  • 19. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.